PTGX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 5.40%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $16,098,398.20

Protagonist Therapeutics Insider Trading History Chart

Protagonist Therapeutics Share Price & Price History

^$45.80

▼ -0.48 (-1.04%)

As of 04/21/2025 05:00 PM ET

Days: 30 | 90 | 365

Protagonist Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/17/2025	William D. Waddill	Director	Sell	4,000	$54.25	$217,000.00	13,130
3/13/2025	Arturo Molina	Insider	Sell	30,514	$55.74	$1,700,850.36	83,892
3/12/2025	Asif Ali	CFO	Sell	24,903	$58.73	$1,462,553.19	62,821
2/19/2025	Dinsesh V. Patel	CEO	Sell	5,359	$38.18	$204,606.62	540,260
11/27/2024	Arturo Molina	Insider	Sell	26,000	$44.70	$1,162,200.00	46,444
11/25/2024	Dinsesh V. Patel	CEO	Sell	78,520	$46.96	$3,687,299.20	435,208
11/25/2024	Suneel Gupta	Insider	Sell	103,437	$46.04	$4,762,239.48	256,174
11/15/2024	Arturo Molina	Insider	Sell	1,906	$40.98	$78,107.88	46,444
9/11/2024	Asif Ali	CFO	Sell	14,203	$44.49	$631,891.47	34,960
9/10/2024	William D. Waddill	Director	Sell	8,000	$45.00	$360,000.00	12,000
7/24/2024	William D. Waddill	Director	Sell	8,000	$40.00	$320,000.00	12,000
6/7/2024	Dinsesh V. Patel	CEO	Sell	35,000	$35.19	$1,231,650.00	515,415
6/7/2024	William D. Waddill	Director	Sell	8,000	$35.00	$280,000.00	12,000
4/18/2024	Asif Ali	CFO	Sell	1,234	$25.11	$30,985.74	37,163
4/1/2024	Dinsesh V. Patel	CEO	Sell	25,000	$28.31	$707,750.00	549,590
3/1/2024	Asif Ali	CFO	Sell	14,248	$32.24	$459,355.52	38,397
3/1/2024	Dinsesh V. Patel	CEO	Sell	30,000	$31.62	$948,600.00	574,590
3/1/2024	William D. Waddill	Director	Sell	12,975	$31.34	$406,636.50	12,000
1/9/2024	Suneel Gupta	Insider	Sell	5,000	$25.00	$125,000.00	187,567

See Full Table

SEC Filings (Institutional Ownership Changes) for Protagonist Therapeutics (NASDAQ:PTGX)

98.63% of Protagonist Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Protagonist Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
4/21/2025	State of Alaska Department of Revenue	33,023	$1.60M	0.0%	-2.5%	0.054%
4/17/2025	Exchange Traded Concepts LLC	27,392	$1.33M	0.0%	+2,572.4%	0.045%
4/15/2025	Assenagon Asset Management S.A.	44,872	$2.17M	0.0%	-14.1%	0.073%
4/15/2025	Handelsbanken Fonder AB	14,400	$0.70M	0.0%	-18.2%	0.023%
4/15/2025	GAMMA Investing LLC	1,203	$58K	0.0%	+153.3%	0.002%
4/14/2025	Yousif Capital Management LLC	22,337	$1.08M	0.0%	-2.5%	0.036%
4/10/2025	Hennion & Walsh Asset Management Inc.	26,066	$1.26M	0.1%	-18.7%	0.042%
4/7/2025	GAMMA Investing LLC	58,177	$2.81M	0.0%	+12,147.8%	0.095%
3/24/2025	Wellington Management Group LLP	940,077	$36.29M	0.0%	+3,025.4%	1.531%
3/18/2025	California State Teachers Retirement System	42,349	$1.64M	0.0%	-0.7%	0.069%
2/20/2025	Mackenzie Financial Corp	21,349	$0.82M	0.0%	+174.6%	0.036%
2/19/2025	Toronto Dominion Bank	340,974	$13.16M	0.0%	N/A	0.572%
2/19/2025	Cache Advisors LLC	10,143	$0.39M	0.1%	N/A	0.017%
2/19/2025	GF Fund Management CO. LTD.	1,251	$48K	0.0%	N/A	0.002%
2/17/2025	UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	287,911	$11.11M	0.0%	-21.8%	0.483%
2/17/2025	Woodline Partners LP	582,327	$22.48M	0.2%	+24.8%	0.977%
2/17/2025	Soleus Capital Management L.P.	275,000	$10.62M	0.7%	N/A	0.461%
2/17/2025	Tidal Investments LLC	21,012	$0.81M	0.0%	-4.8%	0.035%
2/17/2025	State of Wyoming	7,832	$0.30M	0.0%	+11.9%	0.013%
2/17/2025	Toronto Dominion Bank	340,974	$13.16M	0.0%	N/A	0.572%
2/17/2025	Stempoint Capital LP	141,714	$5.47M	1.4%	N/A	0.238%
2/17/2025	Silvercrest Asset Management Group LLC	84,426	$3.26M	0.0%	-1.0%	0.142%
2/17/2025	RTW Investments LP	5,498,545	$212.24M	3.2%	+1.3%	9.226%
2/17/2025	Rafferty Asset Management LLC	95,467	$3.69M	0.0%	+6.2%	0.160%
2/17/2025	ProShare Advisors LLC	20,457	$0.79M	0.0%	+30.5%	0.034%
2/17/2025	Quantedge Capital Pte Ltd	37,200	$1.44M	0.5%	+12.8%	0.062%
2/17/2025	Man Group plc	157,963	$6.10M	0.0%	+182.9%	0.265%
2/17/2025	Nuveen Asset Management LLC	151,197	$5.84M	0.0%	-34.8%	0.254%
2/17/2025	MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.	37,055	$1.43M	0.0%	+4.4%	0.062%
2/17/2025	Jefferies Financial Group Inc.	1,489,495	$57.50M	0.3%	-17.9%	2.499%
2/17/2025	Focus Partners Wealth	425,557	$16.43M	0.0%	-0.3%	0.714%
2/17/2025	Farallon Capital Management LLC	5,930,006	$228.90M	1.2%	+1.2%	9.950%
2/17/2025	D. E. Shaw & Co. Inc.	5,704	$0.22M	0.0%	-78.7%	0.010%
2/17/2025	Deutsche Bank AG	137,932	$5.32M	0.0%	+14.8%	0.231%
2/17/2025	Driehaus Capital Management LLC	339,698	$13.11M	0.1%	-23.7%	0.570%
2/17/2025	Deep Track Capital LP	1,000,000	$38.60M	1.4%	N/A	1.678%
2/17/2025	Crestline Management LP	12,681	$0.49M	0.0%	N/A	0.021%
2/17/2025	Braidwell LP	20,109	$0.78M	0.0%	N/A	0.034%
2/17/2025	BVF Inc. IL	1,900,015	$73.34M	2.5%	+2.7%	3.188%
2/17/2025	Bellevue Group AG	23,718	$0.92M	0.0%	+92.1%	0.040%
2/17/2025	Bank of America Corp DE	134,872	$5.21M	0.0%	+13.4%	0.226%
2/17/2025	BNP Paribas Financial Markets	19,465	$0.75M	0.0%	-4.1%	0.033%
2/17/2025	Ameriprise Financial Inc.	141,387	$5.46M	0.0%	-1.7%	0.237%
2/17/2025	Algert Global LLC	17,720	$0.68M	0.0%	-84.7%	0.030%
2/17/2025	683 Capital Management LLC	410,000	$15.83M	1.0%	-2.4%	0.688%
2/14/2025	Freestone Grove Partners LP	6,644	$0.26M	0.0%	N/A	0.011%
2/14/2025	Comerica Bank	20,558	$0.79M	0.0%	-1.7%	0.034%
2/14/2025	AQR Capital Management LLC	150,097	$5.79M	0.0%	+9.4%	0.252%
2/14/2025	Northern Trust Corp	628,580	$24.26M	0.0%	+8.4%	1.055%
2/14/2025	The Manufacturers Life Insurance Company	124,341	$4.80M	0.0%	+7.4%	0.209%
2/14/2025	Artia Global Partners LP	293,851	$11.34M	4.1%	+136.1%	0.493%
2/14/2025	Boothbay Fund Management LLC	20,188	$0.78M	0.0%	N/A	0.034%
2/14/2025	Virtus ETF Advisers LLC	1,761	$68K	0.0%	-34.3%	0.003%
2/14/2025	New Vernon Capital Holdings II LLC	3,061	$0.12M	0.1%	N/A	0.005%
2/14/2025	Two Sigma Securities LLC	5,505	$0.21M	0.0%	N/A	0.009%
2/14/2025	Voya Investment Management LLC	82,627	$3.19M	0.0%	-27.4%	0.139%
2/14/2025	Price T Rowe Associates Inc. MD	1,392,652	$53.76M	0.0%	+6.4%	2.337%
2/14/2025	Eversept Partners LP	678,787	$26.20M	2.3%	+52.5%	1.139%
2/14/2025	Hsbc Holdings PLC	8,128	$0.31M	0.0%	+38.5%	0.014%
2/14/2025	State of Tennessee Department of Treasury	27,076	$1.05M	0.0%	-2.4%	0.045%
2/14/2025	Tower Research Capital LLC TRC	7,369	$0.28M	0.0%	+1,946.9%	0.012%
2/14/2025	MetLife Investment Management LLC	35,798	$1.38M	0.0%	+5.9%	0.060%
2/13/2025	Marshall Wace LLP	19,716	$0.76M	0.0%	-93.7%	0.033%
2/13/2025	PEAK6 LLC	9,000	$0.35M	0.0%	N/A	0.015%
2/13/2025	Affinity Asset Advisors LLC	130,000	$5.02M	0.7%	N/A	0.218%
2/13/2025	Guggenheim Capital LLC	19,078	$0.74M	0.0%	+141.6%	0.032%
2/13/2025	XTX Topco Ltd	6,744	$0.26M	0.0%	-54.4%	0.011%
2/13/2025	Mariner LLC	17,983	$0.69M	0.0%	+12.5%	0.030%
2/13/2025	Barclays PLC	126,733	$4.89M	0.0%	-0.2%	0.213%
2/13/2025	Covestor Ltd	1,643	$63K	0.0%	+5,200.0%	0.003%
2/13/2025	Kennedy Capital Management LLC	321,526	$12.41M	0.3%	+20.4%	0.539%
2/13/2025	Capital Fund Management S.A.	28,058	$1.08M	0.0%	N/A	0.047%
2/13/2025	Renaissance Technologies LLC	221,167	$8.54M	0.0%	+53.4%	0.371%
2/13/2025	Legal & General Group Plc	152,562	$5.89M	0.0%	-3.1%	0.256%
2/13/2025	Invesco Ltd.	738,952	$28.52M	0.0%	+13.1%	1.240%
2/13/2025	Bank of Montreal Can	6,250	$0.24M	0.0%	+4.5%	0.010%
2/13/2025	Cerity Partners LLC	13,056	$0.52M	0.0%	-8.3%	0.022%
2/13/2025	Sierra Summit Advisors LLC	22,282	$0.86M	0.2%	+5.3%	0.037%
2/13/2025	Envestnet Asset Management Inc.	8,981	$0.35M	0.0%	-29.7%	0.015%
2/13/2025	Aviva PLC	14,627	$0.57M	0.0%	N/A	0.025%
2/13/2025	Wells Fargo & Company MN	38,796	$1.50M	0.0%	+32.1%	0.065%
2/12/2025	ExodusPoint Capital Management LP	29,870	$1.15M	0.0%	N/A	0.050%
2/12/2025	Massachusetts Financial Services Co. MA	32,449	$1.25M	0.0%	N/A	0.054%
2/12/2025	Trexquant Investment LP	92,788	$3.58M	0.0%	+301.8%	0.156%
2/12/2025	Geode Capital Management LLC	1,377,063	$53.17M	0.0%	+0.2%	2.311%
2/12/2025	Franklin Resources Inc.	88,870	$3.43M	0.0%	+8.9%	0.149%
2/12/2025	Alliancebernstein L.P.	68,225	$2.63M	0.0%	-16.7%	0.114%
2/12/2025	Wellington Management Group LLP	940,077	$36.29M	0.0%	+3,025.4%	1.577%
2/12/2025	Arrowstreet Capital Limited Partnership	216,069	$8.34M	0.0%	+36.7%	0.363%
2/12/2025	Pictet Asset Management Holding SA	296,511	$11.45M	0.0%	+3,962.9%	0.498%
2/12/2025	JPMorgan Chase & Co.	576,977	$22.27M	0.0%	+12.9%	0.968%
2/12/2025	WINTON GROUP Ltd	26,768	$1.03M	0.1%	+3.0%	0.045%
2/11/2025	Prudential Financial Inc.	59,998	$2.32M	0.0%	-1.3%	0.101%
2/11/2025	Corebridge Financial Inc.	31,155	$1.20M	0.0%	-7.2%	0.052%
2/11/2025	Advantage Alpha Capital Partners LP	5,742	$0.22M	0.1%	-49.3%	0.010%
2/11/2025	Vanguard Group Inc.	4,220,037	$162.89M	0.0%	+0.1%	7.081%
2/11/2025	KLP Kapitalforvaltning AS	8,700	$0.34M	0.0%	N/A	0.015%
2/11/2025	Sei Investments Co.	24,568	$0.95M	0.0%	-30.0%	0.041%
2/11/2025	American Century Companies Inc.	928,286	$35.83M	0.0%	+61.5%	1.558%
2/11/2025	Summit Global Investments	23,557	$0.91M	0.1%	N/A	0.040%

Data available starting January 2016

See Full Table

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Today's Range

Now: $45.80

$45.07

$46.97

50 Day Range

MA: $45.03

$35.09

$59.76

52 Week Range

Now: $45.80

$24.22

$60.60

Volume

1,189,681 shs

Average Volume

843,844 shs

Market Capitalization

$2.81 billion

P/E Ratio

17.22

Dividend Yield

N/A

Beta

2.3

Who are the company insiders with the largest holdings of Protagonist Therapeutics?: Protagonist Therapeutics' top insider investors include:
Dinesh V Ph D Patel (CEO)
Suneel Gupta (Insider)
Arturo Md Molina (Insider)
Asif Ali (CFO)
William D Waddill (Director)
Learn More about top insider investors at Protagonist Therapeutics.
Who are the major institutional investors of Protagonist Therapeutics?: Protagonist Therapeutics' top institutional shareholders include:
GAMMA Investing LLC — 0.09%
Assenagon Asset Management S.A. — 0.07%
State of Alaska Department of Revenue — 0.05%
Exchange Traded Concepts LLC — 0.04%
Hennion & Walsh Asset Management Inc. — 0.04%
Yousif Capital Management LLC — 0.04%
Learn More about top institutional investors of Protagonist Therapeutics stock.
Which major investors are selling Protagonist Therapeutics stock?: Within the previous quarter, PTGX stock was sold by these institutional investors:
Assenagon Asset Management S.A.
Hennion & Walsh Asset Management Inc.
Handelsbanken Fonder AB
State of Alaska Department of Revenue
Yousif Capital Management LLC
During the previous year, company insiders that have sold Protagonist Therapeutics company stock include:
Dinesh V Ph D Patel (CEO)
Suneel Gupta (Insider)
Arturo Md Molina (Insider)
Asif Ali (CFO)
William D Waddill (Director)
Learn More investors selling Protagonist Therapeutics stock.
Which major investors are buying Protagonist Therapeutics stock?: Within the last quarter, PTGX stock was bought by institutional investors including:
GAMMA Investing LLC
Exchange Traded Concepts LLC
GAMMA Investing LLC